Aurora Cannabis Inc. (ACB)
USD 4.24
(-5.15%)
USD 4.24
(-5.15%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -8.64 Million CAD | 88.21% |
| 2022 | -73.32 Million CAD | 56.44% |
| 2021 | -168.31 Million CAD | -668.32% |
| 2020 | -21.9 Million CAD | -105.94% |
| 2019 | 369.06 Million CAD | -21.82% |
| 2018 | 472.09 Million CAD | 314.06% |
| 2017 | 114.01 Million CAD | 218.88% |
| 2016 | -95.9 Million CAD | -1029.63% |
| 2015 | 10.31 Million CAD | 28.09% |
| 2014 | 8.05 Million CAD | 2225.37% |
| 2013 | -378.98 Thousand CAD | 41.22% |
| 2012 | -644.71 Thousand CAD | 40.99% |
| 2011 | -1.09 Million CAD | -4994.46% |
| 2010 | -21.44 Thousand CAD | 81.66% |
| 2009 | -116.92 Thousand CAD | 92.65% |
| 2008 | -1.59 Million CAD | 2.39% |
| 2007 | -1.63 Million CAD | -280.86% |
| 2006 | -428.06 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | -8.64 Million CAD | 78.92% |
| 2023 FY | -8.64 Million CAD | 88.21% |
| 2023 Q1 | -1.9 Million CAD | 98.87% |
| 2023 Q2 | -41.02 Million CAD | -2052.57% |
| 2022 Q4 | -168.31 Million CAD | -2168.41% |
| 2022 Q3 | -7.42 Million CAD | 77.26% |
| 2022 Q2 | -32.63 Million CAD | 25.35% |
| 2022 FY | -73.32 Million CAD | 56.44% |
| 2022 Q1 | -43.71 Million CAD | 74.03% |
| 2021 Q1 | 33.98 Million CAD | 255.13% |
| 2021 Q2 | 82.04 Million CAD | 141.42% |
| 2021 Q3 | -41.75 Million CAD | -150.89% |
| 2021 Q4 | -168.31 Million CAD | -303.13% |
| 2021 FY | -168.31 Million CAD | -668.32% |
| 2020 Q4 | -21.9 Million CAD | -305.12% |
| 2020 Q3 | 10.68 Million CAD | -90.2% |
| 2020 Q2 | 108.98 Million CAD | -70.81% |
| 2020 Q1 | 373.36 Million CAD | 1.16% |
| 2020 FY | -21.9 Million CAD | -105.94% |
| 2019 Q2 | 445.78 Million CAD | -30.69% |
| 2019 Q1 | 643.2 Million CAD | 36.24% |
| 2019 FY | 369.06 Million CAD | -21.82% |
| 2019 Q3 | 362.5 Million CAD | -18.68% |
| 2019 Q4 | 369.06 Million CAD | 1.81% |
| 2018 Q3 | 292.43 Million CAD | -2.77% |
| 2018 FY | 472.09 Million CAD | 314.06% |
| 2018 Q4 | 472.09 Million CAD | 61.44% |
| 2018 Q2 | 300.78 Million CAD | 109.89% |
| 2018 Q1 | 143.3 Million CAD | 25.69% |
| 2017 Q3 | -21.85 Million CAD | 93.77% |
| 2017 Q4 | 114.01 Million CAD | 621.82% |
| 2017 FY | 114.01 Million CAD | 218.88% |
| 2017 Q1 | -61 Million CAD | 36.4% |
| 2017 Q2 | -350.52 Million CAD | -474.63% |
| 2016 Q4 | -95.9 Million CAD | -3.88% |
| 2016 Q1 | -9.66 Million CAD | -193.72% |
| 2016 Q2 | -35.22 Million CAD | -264.36% |
| 2016 Q3 | -92.32 Million CAD | -162.07% |
| 2016 FY | -95.9 Million CAD | -1029.63% |
| 2015 FY | 10.31 Million CAD | 28.09% |
| 2015 Q3 | 9.54 Million CAD | 7.89% |
| 2015 Q1 | 8.61 Million CAD | 6.95% |
| 2015 Q2 | 8.84 Million CAD | 2.7% |
| 2015 Q4 | 10.31 Million CAD | 8.09% |
| 2014 Q4 | 8.05 Million CAD | 247.56% |
| 2014 FY | 8.05 Million CAD | 2225.37% |
| 2014 Q1 | -1.22 Million CAD | -222.56% |
| 2014 Q3 | 2.31 Million CAD | 33.54% |
| 2014 Q2 | 1.73 Million CAD | 241.96% |
| 2013 Q3 | -575.13 Thousand CAD | -2.46% |
| 2013 FY | -378.98 Thousand CAD | 41.22% |
| 2013 Q1 | -596.35 Thousand CAD | 7.5% |
| 2013 Q2 | -561.29 Thousand CAD | 5.88% |
| 2013 Q4 | -378.98 Thousand CAD | 34.11% |
| 2012 Q2 | -864.03 Thousand CAD | 11.33% |
| 2012 Q4 | -644.71 Thousand CAD | 12.23% |
| 2012 FY | -644.71 Thousand CAD | 40.99% |
| 2012 Q1 | -974.46 Thousand CAD | 10.81% |
| 2012 Q3 | -734.57 Thousand CAD | 14.98% |
| 2011 Q3 | -1.26 Million CAD | -6630.68% |
| 2011 Q1 | -28.55 Thousand CAD | -33.15% |
| 2011 Q2 | -18.8 Thousand CAD | 34.15% |
| 2011 Q4 | -1.09 Million CAD | 13.68% |
| 2011 FY | -1.09 Million CAD | -4994.46% |
| 2010 Q4 | -21.44 Thousand CAD | 61.3% |
| 2010 FY | -21.44 Thousand CAD | 81.66% |
| 2010 Q3 | -55.41 Thousand CAD | 2.52% |
| 2010 Q2 | -56.84 Thousand CAD | -59.74% |
| 2010 Q1 | -35.58 Thousand CAD | 69.57% |
| 2009 Q1 | -1.57 Million CAD | 0.85% |
| 2009 Q4 | -116.92 Thousand CAD | -1148.65% |
| 2009 FY | -116.92 Thousand CAD | 92.65% |
| 2009 Q3 | -9364.00 CAD | 99.46% |
| 2009 Q2 | -1.73 Million CAD | -9.95% |
| 2008 FY | -1.59 Million CAD | 2.39% |
| 2008 Q1 | -1.62 Million CAD | 0.56% |
| 2008 Q3 | -1.59 Million CAD | 1.3% |
| 2008 Q4 | -1.59 Million CAD | 0.46% |
| 2008 Q2 | -1.61 Million CAD | 0.09% |
| 2007 FY | -1.63 Million CAD | -280.86% |
| 2007 Q4 | -1.63 Million CAD | 1.09% |
| 2007 Q3 | -1.64 Million CAD | 1.71% |
| 2007 Q2 | -1.67 Million CAD | -315.36% |
| 2007 Q1 | -403.72 Thousand CAD | 0.0% |
| 2006 FY | -428.06 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Theratechnologies Inc. | 24.87 Million USD | 134.771% |
| Harrow Health, Inc. | 116.41 Million USD | 107.428% |
| Dynavax Technologies Corporation | 106.63 Million USD | 108.11% |
| Biofrontera Inc. | 4.05 Million USD | 313.215% |
| Cronos Group Inc. | -663.32 Million USD | 98.696% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -243.175% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 101.387% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 40.653% |
| RedHill Biopharma Ltd. | -5.18 Million USD | -66.756% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 8192.907% |
| Radius Health, Inc. | 359.28 Million USD | 102.407% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 4485.195% |
| DURECT Corporation | -7.65 Million USD | -12.987% |
| ProPhase Labs, Inc. | 19.23 Million USD | 144.969% |
| Safety Shot Inc | -2.28 Million USD | -278.572% |
| Phibro Animal Health Corporation | 454.84 Million USD | 101.901% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 8.29% |
| Alvotech | 1.06 Billion USD | 100.813% |
| Assertio Holdings, Inc. | -32.52 Million USD | 73.414% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 74.206% |
| Rockwell Medical, Inc. | 4.45 Million USD | 294.075% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 44.687% |
| Procaps Group S.A. | 242.93 Million USD | 103.56% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 93.39% |
| SCYNEXIS, Inc. | -19.35 Million USD | 55.307% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -77.322% |
| Viatris Inc. | 17.13 Billion USD | 100.05% |
| OptiNose, Inc. | 58.06 Million USD | 114.894% |
| SIGA Technologies, Inc. | -148.68 Million USD | 94.184% |
| Tilray Brands, Inc. | 158.97 Million USD | 105.44% |
| PetIQ, Inc. | 351.93 Million USD | 102.457% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 44.687% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 104.878% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | -35.982% |
| Alimera Sciences, Inc. | 55.3 Million USD | 115.636% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 101.987% |
| Silver Spike Investment Corp. | -32.61 Million USD | 73.482% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -480.901% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 157.603% |
| Journey Medical Corporation | -9.7 Million USD | 10.928% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -70.896% |
| Alpha Teknova, Inc. | 1.97 Million USD | 538.095% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | -79.643% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 107.094% |
| PainReform Ltd. | -7.95 Million USD | -8.78% |
| Cosmos Health Inc. | 8.59 Million USD | 200.666% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 305.075% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 335.128% |
| Embecta Corp. | 1.31 Billion USD | 100.659% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -198.06% |
| Talphera, Inc. | -5.72 Million USD | -51.162% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 101.998% |
| Incannex Healthcare Limited | -5.48 Million USD | -57.666% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -5.29% |
| Shineco, Inc. | 29.29 Million USD | 129.525% |
| Procaps Group, S.A. | 242.93 Million USD | 103.56% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 109.18% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 111.538% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 91.058% |
| Alvotech | 1.06 Billion USD | 100.813% |
| Hempacco Co., Inc. | 13.61 Million USD | 163.52% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 221.036% |
| Bright Green Corporation | 1.84 Million USD | 569.56% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 101.885% |
| Kamada Ltd. | -46.43 Million USD | 81.375% |
| Indivior PLC | -33.95 Million USD | 74.529% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 3418.827% |
| Flora Growth Corp. | -713 Thousand USD | -1112.903% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -5.29% |
| Evolus, Inc. | 63.7 Million USD | 113.574% |
| HUTCHMED (China) Limited | -197.45 Million USD | 95.62% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 101.805% |
| Akanda Corp. | 3.9 Million USD | 321.464% |